http://cynata.com/wp-content/uploads/2017/06/RESEARCH-NOTE-CYNATA-1-JUNE-2017.pdf
"Based on NPV based valuation, we believe that Cynata Therapeutics is substantially undervalued at the current share price of AUD 0.57. Using our valuation model and taking into account the future revenues from its Cymerus™ platform, the company’s current total value should be AUD 150-175 million, or AUD 1.67-1.95 per share. This represents a substantial upside from the current share price. "
http://cynata.com/wp-content/uploads/2017/06/RESEARCH-NOTE-CYNATA...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.010(4.00%) |
Mkt cap ! $43.36M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.0¢ | $8.739K | 34.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 19841 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 50000 | 1 |
View Market Depth
| Last trade - 15.44pm 18/10/2024 (20 minute delay) ? |
| CYP (ASX) Chart |